Apolipoprotein A-I (Apolipoprotein A1)

Subscribe to Selected New Research on Apolipoprotein A-I

1958 relevant articles (74 outcomes, 267 trials/studies) found for this Bio-Agent

Description: The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.

Also Known As:

Apolipoprotein A1; Apo A-I; Apolipoprotein AI; Apo A-1; ApoA-I; Apo A-I Isoproteins; Apo A1; Apo AI; ApoA-1; Apolipoprotein A-1; Apolipoprotein A-I Isoprotein-2; Apolipoprotein A-I Isoprotein-4; Apolipoprotein A-I Isoproteins; Apolipoprotein AI Propeptide; Pro-Apo A-I; Pro-Apolipoprotein A-I; Proapolipoprotein AI; Apo A I Isoproteins; Apolipoprotein A 1; Apolipoprotein A I; Apolipoprotein A I Isoprotein 2; Apolipoprotein A I Isoprotein 4; Apolipoprotein A I Isoproteins; Pro Apo A I; Pro Apolipoprotein A I

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Lipoproteins: 17361

Apolipoproteins: 7152

Apolipoproteins A: 655

Apolipoprotein A-I: 1958

apolipoprotein A-I Milano: 24

ETC216: 5

apolipoprotein A-I Tangier: 4

apolipoprotein A-I Giessen: 1

apolipoprotein A-I Paris: 1

apolipoprotein A-I Zaragoza: 1

apolipoprotein A-I Zavalla: 1

human APOA1 protein: 1

apolipoprotein A-I Baltimore

apolipoprotein A-I Helsinki

D-4F peptide

Experts

1.	Navab, Mohamad: 9 articles (05/2008 - 01/2002)
2.	Anantharamaiah, G M: 8 articles (01/2007 - 01/2002)
3.	Fogelman, Alan M: 7 articles (05/2008 - 01/2002)
4.	Hama, Susan: 5 articles (05/2008 - 01/2002)
5.	Van Lenten, Brian J: 5 articles (05/2008 - 08/2002)
6.	Dayer, Jean-Michel: 5 articles (06/2007 - 02/2002)
7.	Rader, Daniel J: 5 articles (01/2007 - 07/2002)
8.	Jungner, I: 5 articles (05/2006 - 12/2001)
9.	Walldius, G: 5 articles (05/2006 - 12/2001)
10.	Scolari, Francesco: 4 articles (05/2008 - 05/2004)

Related Diseases

1.	Atherosclerosis (Atheroma) 03/18/2008 - "CONCLUSIONS: Acute plaque regression observed after short-term apoA-I(Milano) administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis." 06/03/1985 - "One molecular variant, Apo AI-Milano, while leading to a significant reduction of HDL, does not seem to be associated with clinical atherosclerosis, but rather with a protection from the disease. " 05/01/1992 - "Conclusively, apo A1 is effective in preventing the development of experimental atherosclerosis. " 08/18/2003 - "However, overexpression of apolipoprotein A-I in animals has been shown to reduce progression and even induce regression of atherosclerosis, indicating that apolipoprotein A-I is directly protective against atherosclerosis. " 02/14/2006 - "This structure provides a much-needed structural template for exploration of molecular mechanisms by which human apoA-I ameliorates atherosclerosis and inflammatory diseases." Order ALL the reference details at left...
2.	Coronary Artery Disease (Coronary Atherosclerosis) 09/30/2008 - "These findings may be relevant to the study of a novel function of karyopherin beta3 and coronary artery diseases associated with apo A-I." 12/01/1998 - "This study was designed to examine the relationship between polymorphism at the Apo A1 gene and the risk of early coronary artery disease. " 10/01/1991 - "This study describes a variant of familial apoA-I deficiency associated with a moderate risk for premature coronary artery disease. " 01/01/1991 - "Coronary artery disease and apolipoprotein A-I/C-III gene polymorphism: a study of Saudi Arabians." 10/01/1988 - "The results of our study indicate that plasma levels of apo A-I and B are more useful than plasma lipid in detecting the presence or absence of coronary artery disease in a group of male patients undergoing coronary angiography." Order ALL the reference details at left...
3.	Inflammation 08/20/2008 - "In conclusion, adenovirus-mediated ApoA-I overexpression plays a protective effect against LPS-induced systemic inflammation and multiple organ damage in mice. " 08/20/2008 - "To investigate the protective effect of ApoA-I against lipopolysaccharide (LPS)-induced systemic inflammation and multiple organ damage in mice, we established a human ApoA-I overexpression mouse model using recombinant adenovirus vector (AdV-AI). " 08/20/2008 - "Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice." 03/25/2008 - "Moreover, apoA-I GT was associated with decreased cardiac oxidative stress and reduced intramyocardial inflammation. " 01/01/2008 - "This indicates that a single low dose infusion of apoA-I administered after the onset of acute inflammation in carotid arteries decreases neutrophil infiltration and inhibits neutrophil and endothelial cell activation. " Order ALL the reference details at left...
4.	Syndrome 03/01/2008 - "Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity." 01/01/2005 - "BACKGROUND: Studies have shown that hyperuricaemia is independently related to the insulin resistance syndrome and that polymorphisms of the apolipoprotein AI-CIII-AIV cluster are also related to insulin resistance. " 11/14/1986 - "Between 30 and 35% of 'free' apolipoprotein A-I was found in one patient afflicted with the apolipoprotein C-II deficiency syndrome. " 11/15/2006 - "Overall, the median distribution of the apo-B/apo-AI ratio was significantly greater (p <0.0001) in subjects with the Adult Treatment Panel III metabolic syndrome (0.90) than without (0.69). " 06/01/2008 - "Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study." Order ALL the reference details at left...
5.	Vascular Diseases (Vascular Disease) 03/27/2001 - "Despite very low plasma levels of HDL, carriers of the apolipoprotein AI Arg173 --> Cys mutation apoAI(Milano) (AIM) have no apparent increase in risk for atherosclerotic vascular disease. " 05/17/2002 - "Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. " 04/01/2000 - "OBJECTIVE: To measure the blood apolipoprotein A-1 and apolipoprotein B in the fetal circulation in normal pregnancy and in pregnancy with evidence of vascular disease in the fetal umbilical placental circulation defined in the antenatal period by Doppler ultrasound study. " 10/01/2007 - "The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis." 09/01/2006 - "It also relates differences in body fat distribution to differences in the apoB/apoA-I ratio, providing at least part of the answer as to why South Asians may be at increased risk of vascular disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	Lipoproteins (Lipoprotein)
3.	HDL Cholesterol
4.	Cholesterol
5.	Apolipoproteins B (ApoB)
6.	Apolipoproteins
7.	LDL Receptors (LDL Receptor)
8.	Triglycerides (Triacylglycerol)
9.	LDL Cholesterol
10.	Apolipoprotein A-II (Apolipoprotein A2)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Ligation
3.	Diet Therapy (Therapy, Diet)
4.	Renal Dialysis (Hemodialysis)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Atherosclerosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 995 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>